Shopping Cart
- Remove All
- Your shopping cart is currently empty
JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing the recruitment of mutagenic POLζ. JH-RE-06 is an effective REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), which targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 also improves chemotherapy.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $39 | In Stock | |
5 mg | $89 | In Stock | |
10 mg | $163 | In Stock | |
25 mg | $372 | In Stock | |
50 mg | $653 | In Stock | |
100 mg | $1,160 | In Stock | |
1 mL x 10 mM (in DMSO) | $92 | In Stock |
Description | JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing the recruitment of mutagenic POLζ. JH-RE-06 is an effective REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), which targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 also improves chemotherapy. |
Targets&IC50 | Rev1-Rev7:0.42 μM (Kd), Rev1-Rev7:0.78 μM (IC50) |
In vitro | JH-RE-06 unexpectedly causes dimerization of the REV1 CTD at its REV7-binding surface. It also blocks the REV1-REV7 interaction. |
In vivo | In mice, co-administration of JH-RE-06 with cisplatin inhibits the growth of xenograft human melanomas. JH-RE-06 suppresses mutagenic TLS and increases cisplatin-induced toxicity in cultured human and mouse cell lines [1]. |
Molecular Weight | 468.72 |
Formula | C20H16Cl3N3O4 |
Cas No. | 1361227-90-8 |
Smiles | CC(C)CC(=O)c1c(Nc2ccc(Cl)cc2Cl)[nH]c2c(Cl)ccc([N+]([O-])=O)c2c1=O |
Relative Density. | 1.503 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 5 mg/mL (10.67 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.